Evidence map›Paper›PMID 25651180›Full record

ArticleCell metabolism2015

LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion.

Nellie Y Loh, Matt J Neville, Kyriakoula Marinou, Sarah A Hardcastle, Barbara A Fielding, Emma L Duncan, Mark I McCarthy, Jonathan H Tobias, Celia L Gregson, Fredrik Karpe and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cell metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 103 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Reduced Growth and Inflammation in Lrp5Journal of cellular and molecular medicine · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Advances in laboratory medicine · 2024
    Article
  16. Article
  17. Article
  18. Sclerostin and Cardiovascular Disease.Current osteoporosis reports · 2023
    Review
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Nellie Y LohOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK.
Matt J NevilleOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford OX3 7LE, UK.
Kyriakoula MarinouOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; Department of Experimental Physiology, Athens University School of Medicine, Athens 11527, Greece.
Sarah A HardcastleMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK.
Barbara A FieldingOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK.
Emma L DuncanUniversity of Queensland Diamantina Institute, School of Medicine and University of Queensland Centre for Clinical Research, Faculty of Medicine and Biomedical Sciences, University of Queensland, Woolloongabba, QLD 4102, Australia; Department of Endocrinology, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, QLD 4029, Australia.
Mark I McCarthyOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford OX3 7LE, UK.
Jonathan H TobiasMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK.
Celia L GregsonMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK.
Fredrik KarpeOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford OX3 7LE, UK. Electronic address: fredrik.karpe@ocdem.ox.ac.uk.
Constantinos ChristodoulidesOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. Electronic address: costas.christodoulides@ocdem.ox.ac.uk.
University of Oxford · GBUniversity of Bristol · GBOxford Centre for Diabetes, Endocrinology and Metabolism · GBOxford BioMedica (United Kingdom) · GBUniversity of Queensland · AU

Funding

British Heart Foundation PG/12/78/29862Versus Arthritis 20000
6 · The paper itself

Abstract

Common variants in WNT pathway genes have been associated with bone mass and fat distribution, the latter predicting diabetes and cardiovascular disease risk. Rare mutations in the WNT co-receptors LRP5 and LRP6 are similarly associated with bone and cardiometabolic disorders. We investigated the role of LRP5 in human adipose tissue. Subjects with gain-of-function LRP5 mutations and high bone mass had enhanced lower-body fat accumulation. Reciprocally, a low bone mineral density-associated common LRP5 allele correlated with increased abdominal adiposity. Ex vivo LRP5 expression was higher in abdominal versus gluteal adipocyte progenitors. Equivalent knockdown of LRP5 in both progenitor types dose-dependently impaired β-catenin signaling and led to distinct biological outcomes: diminished gluteal and enhanced abdominal adipogenesis. These data highlight how depot differences in WNT/β-catenin pathway activity modulate human fat distribution via effects on adipocyte progenitor biology. They also identify LRP5 as a potential pharmacologic target for the treatment of cardiometabolic disorders.

Indexed as

AdipogenesisBody Fat DistributionAdipose TissueAdultAllelesbeta CateninDose-Response Relationship, DrugFemaleHealthy VolunteersHumansLow Density Lipoprotein Receptor-Related Protein-5MaleMiddle AgedMutationStem CellsThiazolidinedionesbeta CateniniCTR14 compoundLow Density Lipoprotein Receptor-Related Protein-5LRP5 protein, humanThiazolidinediones

Identifiers

PMID25651180
PMCPMC4321886
OpenAlexW2064879520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.